News Invites Biocore Co., Ltd.

Equities

A216400

KR7216400002

End-of-day quote Korea S.E. Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
8,800 ^KRW	-3.30%		-2.87%	-5.38%

2023	CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	CI
2023	Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	12-27	CI
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	16/05/23	CI
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.	14/07/22	CI
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.	13/07/22	CI
Biocore Co., Ltd. announced that it has received KRW 41.999997 billion in funding	30/03/21	CI
Biocore Co., Ltd. announced that it expects to receive KRW 41.999997 billion in funding	16/02/21	CI
BioCore Inc. Signs Agreement with Osprey Medical, Inc	25/11/20	CI
Biocore Co., Ltd. announced that it has received KRW 7.99999527 billion in funding	07/07/20	CI
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.	30/06/20	CI
Biocore Co., Ltd. announced that it expects to receive KRW 7.99999527 billion in funding	29/06/20	CI
Biocore Co., Ltd. announced that it expects to receive KRW 5.04114275 billion in funding	30/09/19	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.	02/08/16	CI
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.	01/08/16	CI
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.	01/08/16	CI
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.	28/07/16	CI
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.	27/10/15	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.	27/10/15	CI
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.	21/10/15	CI
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.	18/08/15	CI
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea	27/03/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Invites Biocore Co., Ltd.

Equities

A216400

KR7216400002

Summary

Filters